Table 1 V565 displays similar potency to approved anti-TNFα agents.

Assay Method	Antibody	TNFα	Functional Readout	Potency IC₅₀ or K_D (nM)
Biosensor	V565	sTNFα	TNFα association and dissociation kinetics	0.017^b
Biosensor	adalimumab^a	sTNFα	TNFα association and dissociation kinetics	0.005^b
ELISA	V565	sTNFα	Inhibition of TNFα-TNFR2 interaction	0.41^c
ELISA	adalimumab	sTNFα	Inhibition of TNFα-TNFR2 interaction	0.21^c
ELISA	V565	sTNFα	Inhibition of TNFα-TNFR1 interaction	0.6^c
ELISA	adalimumab	sTNFα	Inhibition of TNFα-TNFR1 interaction	0.2^c
L929 cell viability	V565	sTNFα	Inhibition of TNFα-induced cell cytotoxicity	0.27^d
L929 cell viability	adalimumab	sTNFα	Inhibition of TNFα-induced cell cytotoxicity	0.17^d
HEK-NFkB-cells	V565	sTNFα	Inhibition of TNFα-induced NFkB-SEAP	0.3^d
HEK-NFkB-cells	V565	tmTNFα	Inhibition of tmTNFα-CHO induced NFkB-SEAP	5.2^d
HEK-NFkB-cells	adalimumab	tmTNFα	Inhibition of mTNFα-CHO induced NFkB-SEAP	3.1^d
HEK-NFkB-cells	infliximab	tmTNFα	Inhibition of mTNFα-CHO induced NFkB-SEAP	3.8^d

^aAdalimumab Fab fragment.
^bK_D equilibrium dissociation constant.
^cIC₅₀ concentration of V565 or adalimumab required to achieve 50% inhibition of maximal sTNFα-binding to TNFR1 or TNFR2 in a plate ELISA format.
^dIC₅₀ concentration of V565 or adalimumab required to achieve 50% inhibition of maximal TNFα-induced response.

Quick links

Search